Executive summary: Stages of Reproductive Aging Workshop (STRAW)

Soules, Michael R.; Sherman, Sherry; Parrott, Estella C.; Rebar, Robert W.; Santoro, Nanette; Utian, Wulf H.; Woods, Nancy Fúgate

doi:10.1080/cmt.4.4.267.272

Cited by 406 publications

(243 citation statements)

References 2 publications

(1 reference statement)

Supporting

Mentioning

230

Contrasting

Unclassified

Order By: Relevance

“…Menstrual changes are therefore considered to be an early manifestation of ovarian dysfunction. A decrease in the follicle count with age indicates the onset of cycle irregularity and the final cessation of menses (46,47), which is the final step in the process of ovarian aging. Moreover, the corresponding age-related decline in oocyte quality is widely known to be a major impetus for low pregnancy rates in aging females.…”

Section: Discussionmentioning

confidence: 99%

The protective effects of human umbilical cord mesenchymal stem cells on damaged ovarian function: A comparative study

Zhang

Xiong

et al. 2016

BST

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

The protective effects of human umbilical cord mesenchymal stem cells on damaged ovarian function: A comparative study

Zhang

Xiong

et al. 2016

BST

View full text Add to dashboard Cite

“…Our population was composed of younger women, half of whom were in the menopausal transition or in early postmenopause (28), when menopause symptoms are most severe and bone loss is accelerated.…”

Section: Discussionmentioning

confidence: 99%

“…The participation rate throughout the trial was high, and the adherence to treatment was assessed by estradiol measurements. We offered participation in the study to all women with SLE at different postreproductive stages, including the menopausal transition and early or late postmenopause (28), who attended our center, including those with variable disease activity and those who tested positive for aPL, provided they had no history of recent thrombosis. Twenty-seven percent of the patients had undergone premature menopause, and the mean BMI was Ͻ27 kg/m 2 .…”

Section: Discussionmentioning

confidence: 99%

“…Menopause status was assigned according to the Stages of Reproductive Aging Workshop definitions (28): women who had presented with endometrial bleeding within the 12 months prior to the study initiation were considered to be in the menopausal transition, whereas those with amenorrhea of at least 12 months' duration were postmenopausal. Early postmenopausal women included those with Յ5 years of amenorrhea, whereas late postmenopausal women were those with Ͼ5 years of amenorrhea.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Menopause hormonal therapy in women with systemic lupus erythematosus

Sánchez‐Guerrero

González-Pérez

Durand-Carbajal

et al. 2007

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. To evaluate the effects of menopause hormonal therapy on disease activity in women with systemic lupus erythematosus (SLE).Methods. We conducted a double-blind, randomized clinical trial involving 106 women with SLE who were in the menopausal transition or in early or late postmenopause. Patients received a continuoussequential estrogen-progestogen regimen (n ‫؍‬ 52) or placebo (n ‫؍‬ 54). Disease activity was assessed at baseline and at 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24 months, according to the SLE Disease Activity Index (SLEDAI). The primary outcome measure was global disease activity, estimated by measuring the area under the SLEDAI curve. Secondary outcome measures included maximum SLEDAI score, change in SLEDAI score, incidence of lupus flares, median time to flare, medication use, and adverse events. Results were studied using intent-totreat analysis.Results. At baseline, demographic and disease characteristics were similar in both groups. Mean ؎ SD SLEDAI scores were 3.5 ؎ 3.3 and 3.1 ؎ 3.4 in the menopause hormonal therapy and placebo groups, respectively (P ‫؍‬ 0.57). Disease activity remained mild and stable in both groups throughout the trial. There were no significant differences between the groups in global or maximum disease activity, incidence or probability of flares, or medication use. Median time to flare was 3 months in both groups. Thromboses occurred in 3 patients who received menopause hormonal therapy and in 1 patient who received placebo. One patient in each group died during the trial due to sepsis.Conclusion. Menopause hormonal therapy did not alter disease activity during 2 years of treatment. However, an apparently increased risk of thrombosis seems to be a real threat in women with SLE who receive menopausal hormone therapy.

show abstract

“…Based on these characteristics, the American Society for Reproductive Medicine proposed the "Stages of Reproductive Aging Workshop (STRAW) staging system" (8). We also divided 231 healthy women into 7 stages by regularity of menstruation and FSH level : 1) women with regular menstruation cycle and normal FSH level (group A), 2) women with regular menstruation cycle and elevated FSH level (!10 mIU/ml) (late reproductive stage, group B), 3) women with irregular menstruation cycle and elevated FSH level (early menopausal transition, group C), 4) women who had irregular menstruation cycle in which the interval of amenorrhea was more than 2 months and elevated FSH level (late menopausal transition, group D), 5) women for whom less than 1 year had passed since menopause (group E), 6) women for whom less than 5 years had passed since menopause (group F) and 7) women for whom more than 5 years had passed since menopause (group G).…”

Section: Changes In Testosterone Level In Womenmentioning

confidence: 99%

Androgen in postmenopausal women

et al. 2012

View full text Add to dashboard Cite

Dynamic changes in circulating estradiol level, including increase at menarche and decrease at menopause, occur in a woman's lifetime. Circulating estradiol levels decrease drastically during the menopausal transition, though the levels differ among races. It has been reported that estradiol levels in both Japanese and Chinese women were lower than those in Caucasians, Hispanic and AfricanAmericans (1).Based on data obtained in a previous study (2), we re-analyzed data for 169 healthy men and 252 healthy women aged from 40 to 85 years in the population-based study with addition of data for premenopausal women. Change in circulating estradiol in women from the menopausal transition to postmenopause is characterized as follows : high estradiol level in premenopausal women is drastically decreased and estradiol level in postmenopausal women is significantly lower than that in agematched men. Mean estradiol levels were shown to be 20.1 pg/ml in men and 6.1 pg/ml in postmenopausal women (Figure 1). This dynamic decrease in REVIEW Androgen in postmenopausal women

show abstract

Executive summary: Stages of Reproductive Aging Workshop (STRAW)

Abstract: A select group of investigators attended a structured workshop, the Stages of Reproductive Aging Workshop (STRAW), at Park City, Utah, USA, in July 2001, which addressed the need in women for a staging system as well as the confusing nomenclature for the reproductive years.

Cited by 406 publications

References 2 publications

The protective effects of human umbilical cord mesenchymal stem cells on damaged ovarian function: A comparative study

The protective effects of human umbilical cord mesenchymal stem cells on damaged ovarian function: A comparative study

Menopause hormonal therapy in women with systemic lupus erythematosus

Androgen in postmenopausal women

Contact Info

Product

Resources

About